Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Medicenna Therapeutics Corp T.MDNA

Alternate Symbol(s):  MDNAF

Healthcare Biotechnology
Medicenna Therapeutics Corp. is a clinical-stage immunotherapy company focused on developing highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Its long-acting IL-2 Superkine, MDNA11, is a IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing... see more

Recent & Breaking News (TSX:MDNA)

Medicenna Reports Third Quarter Fiscal 2023 Financial Results and Operational Highlights

GlobeNewswire February 7, 2023

Medicenna to Present at the 2023 Guggenheim Oncology Conference

GlobeNewswire January 31, 2023

Medicenna to Announce Third Quarter Fiscal 2023 Financial Results and Operational Highlights on Tuesday, February 7, 2023

GlobeNewswire January 26, 2023

Medicenna (TSX:MDNA) obtains new patent for methods of treating cancer

Azuka Onwuka January 5, 2023

Medicenna Strengthens Intellectual Property Protection for MDNA11 and BiSKITs(TM) Programs with Issuance of U.S. Patent

GlobeNewswire January 5, 2023

Medicenna Presents Updated Clinical Data from Dose Escalation Portion of Phase 1/2 ABILITY Study of MDNA11 at the SITC Annual Meeting

GlobeNewswire November 10, 2022

Medicenna (TSX:MDNA) reports Q2 fiscal 2023 financial results & operational highlights

Jonathon Brown November 4, 2022

Medicenna Reports Second Quarter Fiscal 2023 Financial Results and Operational Highlights

GlobeNewswire November 4, 2022

Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

GlobeNewswire October 28, 2022

Medicenna to Announce Second Quarter Fiscal 2023 Financial Results and Operational Highlights on Friday, November 4, 2022

GlobeNewswire October 25, 2022

Medicenna Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting

GlobeNewswire October 5, 2022

Medicenna Extends Period to Exercise Certain Warrants

GlobeNewswire September 30, 2022

Medicenna Reports Confirmed Partial Response in Pancreatic Cancer and Clinical Update on MDNA11's Monotherapy Dose Escalation Portion of the Ongoing Phase 1/2 ABILITY Study

GlobeNewswire September 28, 2022

Medicenna Presents Preclinical Data Demonstrating Anti-Tumor Activity of its Anti-PD1-IL-2 BiSKIT and Long-Acting IL-4/IL-13 Super-antagonist at Cytokines 2022

GlobeNewswire September 22, 2022

Medicenna Announces Results of Annual Meeting of Shareholders

GlobeNewswire September 21, 2022

Medicenna (TSX:MDNA) announces clinical collaboration with Merck

Trevor Abes  September 13, 2022

Medicenna Announces Clinical Collaboration with Merck to evaluate MDNA11 in combination with KEYTRUDA® (pembrolizumab) in ABILITY Trial

GlobeNewswire September 13, 2022

Medicenna to Present at Investor and Scientific Conferences in September

GlobeNewswire September 8, 2022

Medicenna (TSX:MDNA) reports fiscal Q1 2023 financial results

Jonathon Brown August 15, 2022

Medicenna Reports First Quarter Fiscal 2023 Financial Results and Operational Highlights

GlobeNewswire August 15, 2022